FDG pet studies during treatment:: Prediction of therapy outcome in head and neck squamous cell carcinoma
FDG pet studies during treatment:: Prediction of therapy outcome in head and neck squamous cell carcinoma
复制标题
DOI：
10.1002/hed.10037
复制
发表时间：
2002-02-01
影响因子：
2.9
通讯作者：
Strand, SE
中科院分区：
文献类型：
--
作者：
Brun, E;Kjellén, E;Strand, SE
背景正电子发射断层扫描（PET）提供了体内组织的代谢信息。本研究的目的是评估2-[（18）F]氟-2-脱氧-D-葡萄糖（FDG）PET在预测局部晚期HNSCC治疗结果（肿瘤反应、生存率和局部控制）中的价值。1993~1999年对47例患者在根治性治疗前（PET 1）和根治性治疗后（PET 2）1~3周进行PET检查，评价代谢率（MR）和FDG标准摄取值（SUV）。所有患者均接受放疗，10例同时接受新辅助化疗。中位随访时间为3.3年。PET2时低和高MR FDG，以中位数为界值，分别与96%和62%的完全缓解相关（p = 0.007），与72%和35%的5年总生存率相关（p = 0.0042），与96%和55%的局部控制相关（p = 0.002）。HNSCC治疗早期的FDG PET与肿瘤反应、生存率和局部控制相关。(C)2002年John Wiley Sons，Inc.
Background. Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC.Methods. Between 1993 and 1999 47 patients underwent PET before (PET1) and after (PET2) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years.Results. Low and high MR FDG at PET2, with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively.Conclusions. FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. (C) 2002 John Wiley Sons, Inc.